dc.contributor.author |
McCurdy S. |
|
dc.contributor.author |
Liu C. |
|
dc.contributor.author |
Yap J. |
|
dc.contributor.author |
Boisvert W. |
|
dc.date.accessioned |
2018-04-05T07:09:30Z |
|
dc.date.available |
2018-04-05T07:09:30Z |
|
dc.date.issued |
2017 |
|
dc.identifier.issn |
1043-4666 |
|
dc.identifier.uri |
http://dspace.kpfu.ru/xmlui/handle/net/129778 |
|
dc.description.abstract |
© 2017 Elsevier Ltd. IL-37 is a member of the IL-1 family, but unlike most other members of this family of cytokines, it has wide-ranging anti-inflammatory properties. Initially shown to bind IL-18 binding protein and prevent IL-18-mediated inflammation, its known role has been expanded to include distinct pathways, both intracellular involving the transcription factor Smad3, and extracellular via binding to the orphan receptor IL-1R8. A number of recent publications investigating the role of IL-37 in atherosclerosis and ischemic heart disease have revealed promising therapeutic value of the cytokine. Although research concerning the role of IL-37 and its mechanism in atherosclerosis is relatively scant, there are a number of well-known atherosclerotic processes that this cytokine can mediate with the potential of modulating the disease progression itself. This review will probe in detail the effects of IL-37 on important pathological processes such as inflammation, dysregulated lipid metabolism, and apoptosis, by analyzing existing data as well as exploring the potential of this cytokine to influence these properties. |
|
dc.relation.ispartofseries |
Cytokine |
|
dc.subject |
Anti-inflammatory properties |
|
dc.subject |
Atherosclerosis |
|
dc.subject |
IL-37 |
|
dc.title |
Potential role of IL-37 in atherosclerosis |
|
dc.type |
Article in Press |
|
dc.collection |
Публикации сотрудников КФУ |
|
dc.source.id |
SCOPUS10434666-2017-SID85030552867 |
|